NASDAQ$ETNB
89Bio Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
89bio reported financial results for Q4 and full year 2019, highlighting progress with BIO89-100 clinical trials and a successful IPO.
89bio reported its Q4 and full year 2019 financial results, noting the initiation of the Phase 1b/2a clinical trial for BIO89-100 in NASH, planned initiation of Phase 2 study in SHTG, and the completion of an upsized initial public offering.
- Initiated dosing in Phase 1b/2a clinical trial evaluating BIO89-100 in patients with NASH or NAFLD.
- Phase 2 clinical trial evaluating BIO89-100 in patients with SHTG is on track for initiation in the first half of 2020.
- Completed an upsized IPO on November 13, 2019, with gross proceeds of approximately $97.6 million.
- Cash and cash equivalents were $93.4 million as of December 31, 2019, including net proceeds from the IPO.
Headline financials
Revenue & EPS history
89Bio · Revenue · Quarterly
$0
Forward guidance
89bio expects 2020 to be a transformative year with topline data from the Phase 1b/2a NASH study expected in the second half of 2020 and planned initiation of the Phase 2 study in SHTG in the first half of 2020.
Tailwinds
- Topline data from Phase 1b/2a NASH study expected in 2H20.
- Planned initiation of Phase 2 SHTG study in 1H20.
- BIO89-100 demonstrated consistent beneficial effects in preclinical studies.
- BIO89-100 demonstrated a favorable tolerability profile and dose-proportional pharmacokinetics in Phase 1a clinical trial.
- Statistically significant improvements in key lipid parameters were observed for two weeks after a single dose of BIO89-100.
Headwinds
- Expectations regarding the enrollment, completion and outcome of 89bio’s proof of concept Phase 1b/2a clinical trial evaluating BIO89-100 in patients with NASH or patients with NAFLD and a high risk of NASH.
- Expectations regarding the timing, completion and outcome of 89bio’s proof of concept Phase 2 clinical trial evaluating BIO89-100 in patients with SHTG.
- The unpredictable relationship between preclinical study results and clinical study results.
- Liquidity and capital resources.
- Other risks and uncertainties identified in 89bio’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, filed December 18, 2019 with the SEC and other subsequent disclosure documents filed with the SEC.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports
-0.1%
Avg return
Earnings day
-4.6%
Avg return
5 days after
-2.8%
Avg return
30 days after
54%
13 / 24 earnings
Positive
+14.8%
Q4 2019
Best reaction
-19.4%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +1.7% | +1.3% | -1.7% | |
| Q1 2025 | -3.7% | -4.1% | +18.6% | |
| Q4 2024 | -1.0% | -7.1% | -3.7% | |
| Q3 2024 | +2.8% | -10.9% | -20.6% | |
| Q2 2024 | -10.9% | -11.8% | -0.9% | |
| Q1 2024 | -3.5% | +0.8% | -10.2% | |
| Q4 2023 | +7.3% | -0.2% | -1.3% | |
| Q3 2023 | -11.8% | — | — | |
| Q2 2023 | +5.3% | — | — | |
| Q1 2023 | +1.3% | — | — | |
| Q4 2022 | -1.1% | — | — | |
| Q3 2022 | +14.2% | — | — | |
| Q2 2022 | +3.6% | — | — | |
| Q1 2022 | +14.6% | — | — | |
| Q4 2021 | +5.1% | — | — | |
| Q3 2021 | +1.4% | — | — | |
| Q2 2021 | +1.1% | — | — | |
| Q1 2021 | -19.4% | — | — | |
| Q4 2020 | -4.7% | — | — | |
| Q3 2020 | -0.8% | — | — | |
| Q2 2020 | +1.6% | — | — | |
| Q1 2020 | -6.2% | — | — | |
| Q4 2019 | +14.8% | — | — | |
| Q3 2019 | -13.5% | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro